［Abstract］　Biliary tract cancer(BTC) is a malignant tumor originating from the mucosal epithelial cells of intrahepatic and extrahepatic bile ducts and gallbladder walls, accounting for about 3% of malignant tumors of the digestive system. The incidence and mortality rates of BTC have been increasing in recent years. Based on its characteristics of clinical and pathological heterogeneity, BTC is difficult to be found in the early stage. Once diagnosed, BTC is often at an advanced stage with a poor prognosis. For a long time, chemotherapy is the only treatment for patients with BTC at an advanced stage, but the effect is not satisfactory. In recent years, with the rise of precision therapy, especially the continuous innovation of molecular targeted drugs in the field of BTC, there are more and more treatment options for advanced BTC. The approval of fibroblast growth factor receptor(FGFR) inhibitor pemigatinib has officially opened the new door to molecular targeting therapy for biliary tract tumors. At present, there have been a variety of clinical applications or experimental studies on different targeted drugs of advanced BTC. This paper reviews and summarizes these clinical applications or experimental studies in order to provide some reference value for guiding clinical practice.]]> 2022/3/8 10:33:08 ZHONG Jing-tao, SHI Xue-tao 4true ［Abstract］　Surgical resection is the preferred treatment and the only possible cure for intrahepatic cholangiocarcinoma(ICC). R₀ resection is an important factor affecting the surgical prognosis of ICC. On the basis of ensuring R₀ resection and the surgical safety, the resection margin should be greater than 10 mm. Whether lymph node metastasis exists is one of the most important prognostic factors of surgery for ICC. Lymphadenectomy can improve the prognosis of the patients, and adjuvant postoperative systemic therapy can prolong the survival of the patients. For some patients with initially unresectable ICC, neoadjuvant therapy is an effective measure that may enable the patients to obtain the opportunity of radical surgical resection.]]> 2022/3/8 10:33:08 ZHANG Zhi-hao, LIU Feng 3true ［Abstract］　The incidence of hepatocellular carcinoma(HCC) is high, and hepatitis B virus(HBV) and hepatitis C virus(HCV) infections are the main causes of HCC. In recent years, the prevalence of metabolic diseases such as obesity and type 2 diabetes has accelerated the occurrence of non-alcoholic fatty liver disease(NAFLD), resulting in the occurrence of NAFLD-related HCC(NAFLD-HCC) increasing year by year. However, it remains unclear whether NAFLD-HCC and virus-related HCC have similar pathogenesis, prevention, surveillance and treatment strategies. This paper reviews the above problems and provides reference for the prevention and treatment of NAFLD-HCC.]]> 2022/3/8 10:33:08 XIE Si, LI Le-qun 2true ［Abstract］　Objective　To compare the effects between laparoscopic cholecystectomy(LC) combined with endoscopic retrograde cholangiopancreatography(ERCP) and LC combined with laparoscopic common bile duct exploration(LCBDE) on the treatment of cholecystolithiasis complicated with choledocholithiasis. Methods　Sixty-four patients with cholecystolithiasis complicated with choledocholithiasis who were admitted to Wuming Hospital of Guangxi Medical University from January 2019 to December 2021 were retrospectively collected. Among the 64 patients, 32 cases receiving LC+LCBDE(LCBDE group) and 32 cases receiving LC+ERCP(ERCP group) were screened out according to the plan. The clinical indicators were compared between the two groups. Results　The operation time in the ERCP group［(3.0±1.0)d］ was shorter than that in the LCBDE group［(4.7±1.4)d］, and the postoperative hospitalization time in the ERCP group［(5.3±2.0)d］ was shorter than that in the LCBDE group［(13.1±4.7)d］, and the hospitalization costs in the ERCP group were lower than those in the LCBDE group, and the differences were statistically significant(P<0.05). Conclusion　LC+LCBDE and LC+ERCP are both effective and safe methods for the treatment of cholecystolithiasis complicated with choledocholithiasis, but LC+ERCP can shorten the operation time and the hospitalization time, and reduce the hospitalization costs compared with LC+LCBDE. For the indications, LC+ERCP can be used as the preferred treatment method.]]> 2022/3/8 10:33:08 HUANG Qiang-song, HU Fu-jing, HUANG Hai 1true